Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration

Curr Radiopharm. 2020;13(2):159-163. doi: 10.2174/1874471012666190927115331.

Abstract

Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals.

Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur. In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.

Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride.

Conclusion: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.

Keywords: Ra-223 dichloride; alpha particle therapy; life quality; lymphedema; radiopharmaceutical adverse effects.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Compression Bandages
  • Exercise Therapy
  • Female
  • Humans
  • Lymphedema / chemically induced*
  • Lymphedema / therapy
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Radioisotopes / adverse effects
  • Radioisotopes / therapeutic use
  • Radium / adverse effects*
  • Radium / therapeutic use

Substances

  • Antineoplastic Agents
  • Radioisotopes
  • radium Ra 223 dichloride
  • Radium